Prostate Cancer Clinical Trial

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

Summary

This study will assess the efficacy and safety of capivasertib plus docetaxel versus placebo plus docetaxel in participants with metastatic castration resistant prostate cancer (mCRPC), all participants will receive the docetaxel with steroid therapy and receive androgen deprivation therapy. The intention of the study is to demonstrate that the combination of capivasertib plus docetaxel is superior to placebo plus docetaxel with respect to the overall survival of study participants, when overall survival is defined as the time from randomization until the date of death due to any cause.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Histologically-confirmed prostate adenocarcinoma without neuroendocrine or small cell cancers
Metastatic disease documented prior to randomisation by clear evidence of ≥ 1 bone lesion (defined as 1 lesion with positive uptake on bone scan) and/or ≥ 1 soft tissue lesion (measurable or non-measurable)
Patient must have been previously treated with a next generation hormonal agent (NHA), ie, abiraterone, enzalutamide, apalutamide or darolutamide, for prostate cancer for at least 3 months and shown evidence of disease progression (radiological or via PSA assessment) while receiving the NHA
Evidence of mCRPC with progression of disease despite androgen deprivation therapy (ADT) and after anti-androgen withdrawal if applicable
Serum testosterone level ≤ 50 ng/dL
Candidate for docetaxel and steroid therapy
Ongoing ADT with LHRH agonist, LHRH antagonist, or bilateral orchiectomy
Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance status 0 to 1 and anticipated minimum life expectancy of 12 weeks
Confirmation that archival formalin-fixed paraffin-embedded (FFPE) tumour tissue sample which meets the minimum pathology and sample requirements is available to send to the central laboratory
Able and willing to swallow and retain oral medication
Agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm

Exclusion Criteria:

Radiotherapy with a wide field of radiation within 4 weeks before start of study treatment
Major surgery (excl. placement of vascular access, transurethral resection of prostate, bilateral orchiectomy, internal stents) within 4 weeks of start of study treatment
Brain metastases,or spinal cord compression (unless spinal cord compression is asymptomatic, treated and stable and not requiring steroids for at least 4 weeks prior to start of study treatment)

Any of the following cardiac criteria:

i. Mean resting corrected QT interval (QTc) >470 msec from 3 consecutive ECGs ii. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG iii. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age,or any concomitant medication known to prolong the QT interval iv. Experience of any of the following procedures or conditions in the preceding 6months: coronary artery bypass graft, vascular stent, myocardial infarction, unstable angina pectoris, congestive heart failure NYHA Grade ≥2 v. Uncontrolled hypotension - systolic blood pressure <90 mmHg and or diastolic blood pressure <50 vi. Cardiac ejection fraction outside institutional range of normal <50% (whichever is higher) as measured by echocardiogram (or multiple-gated acquisition scan if an cannot be performed inconclusive)

Clinically significant abnormalities of glucose metabolism as defined by any of the following:

i. Patients with diabetes mellitus (DM) type 1 or DM type 2 requiring insulin treatment ii. HbA1c ≥8.0% (63.9 mmol/mol)

Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:

i. Absolute neutrophil count < 1.5x 10^9/L ii. Platelet count < 100x 10^9/L iii. Haemoglobin < 9 g/dL (< 5.59 mmol/L) iv. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5x upper limit of normal (ULN) if no demonstrable liver metastases or > 5x ULN in the presence of liver metastases. Elevated alkaline phosphatase (ALP) is not exclusionary if due to the presence of bone metastases and liver function is otherwise considered adequate in the investigator's judgement v. Total bilirubin > 1.5x ULN (participants with confirmed Gilbert's syndrome may be included in the study with a higher value) vi. Creatinine clearance < 50 mL/min per the Cockcroft and Gault formula without the need for chronic dialysis;

As judged by the investigator, any evidence of diseases (such as severe or uncontrolled systemic diseases, including uncontrolled hypertension, renal transplant and active bleeding diseases), which, in the investigator's opinion, makes it undesirable for the patient to participate in the study or that would jeopardise compliance with the protocol.
Refractory nausea and vomiting, malabsorption syndrome, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection, or other condition that would preclude adequate absorption of capivasertib
Any other disease, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contra-indicates the use of an investigational drug, may affect the interpretation of the results, render the patient at high risk from treatment complications or interferes with obtaining informed consent. Evidence of dementia, altered mental status, or any psychiatric condition that would prohibit understanding or rendering of informed consent.
Previous allogeneic bone marrow transplant or solid organ transplant
History of another primary malignancy except for malignancy treated with curative intent with no known active disease ≥5 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include basal cell carcinoma of the skin and squamous cell carcinoma of the skin that has undergone potentially curative therapy.
Persistent toxicities (CTCAE Grade ≥2) caused by previous anticancer therapy, excluding alopecia. Patients with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss) after consultation with the medical monitor
Known to have active hepatitis infection, positive hepatitis C antibody, hepatitis B virus surface antigen, or hepatitis B virus core antibody at screening.
Known to have human immunodeficiency virus (HIV) with a CD4+ T-cell count < 350 cells/uL or a history of an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection within the past 12 months.
Known to have active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).

Treatment with any of the following:

i. Prior chemotherapy for CRPC. Chemotherapy for metastatic or localized HSPC (including docetaxel) is allowed provided that chemotherapy was completed ≥ 6months before randomisation and progression of the prostate cancer occurred ≥ 6months after the completion of therapy.

ii. Prior exposure to AKT inhibitors or PI3K inhibitors iii. Any investigational agents or study drugs from a previous clinical study within 30 days or 5 half-lives (whichever is longer) of the first dose of study treatment iv. Any other immunotherapy, immunosuppressant medication (other than corticosteroids) or anticancer agents (except ADT) within 3 weeks of the first dose of study treatment v. Strong inhibitors or inducers of cytochrome P450 (CYP)3A4 within 2 weeks prior to the first dose of study treatment (3 weeks for St John's wort), or drugs that are sensitive to inhibition of CYP3A4 within 1 week prior to the first dose of study treatment

Drugs known to prolong the QT interval within 5 half-lives of the first dose of study treatment
History of hypersensitivity to active or inactive excipients of capivasertib, docetaxel, or drugs with a similar chemical structure or class
Any restriction or contraindication based on the local prescribing information that would prohibit the use of docetaxel

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

790

Study ID:

NCT05348577

Recruitment Status:

Recruiting

Sponsor:

AstraZeneca

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 207 Locations for this study

See Locations Near You

Research Site
Phoenix Arizona, 85004, United States
Research Site
Beverly Hills California, 90211, United States
Research Site
Fresno California, 93701, United States
Research Site
Los Angeles California, 90095, United States
Research Site
Sacramento California, 95817, United States
Research Site
San Francisco California, 94115, United States
Research Site
Santa Monica California, 90404, United States
Research Site
Santa Rosa California, 95403, United States
Research Site
Aurora Colorado, 80045, United States
Research Site
Lakewood Colorado, 80228, United States
Research Site
Orange City Florida, 32763, United States
Research Site
Chicago Ridge Illinois, 60415, United States
Research Site
Chicago Illinois, 60612, United States
Research Site
Baltimore Maryland, 21201, United States
Research Site
Baltimore Maryland, 21287, United States
Research Site
Minneapolis Minnesota, 55404, United States
Research Site
Minneapolis Minnesota, 55416, United States
Research Site
Hackensack New Jersey, 07601, United States
Research Site
Bronx New York, 10461, United States
Research Site
White Plains New York, 10601, United States
Research Site
Portland Oregon, 97223, United States
Research Site
Bala-Cynwyd Pennsylvania, 19004, United States
Research Site
Hershey Pennsylvania, 17033, United States
Research Site
Philadelphia Pennsylvania, 19107, United States
Research Site
Philadelphia Pennsylvania, 19111, United States
Research Site
Greenville South Carolina, 29605, United States
Research Site
Watertown South Dakota, 57201, United States
Research Site
Chattanooga Tennessee, 37404, United States
Research Site
Nashville Tennessee, 37203, United States
Research Site
Austin Texas, 78731, United States
Research Site
Dallas Texas, 75235, United States
Research Site
Kingwood Texas, 77339, United States
Research Site
San Antonio Texas, 78217, United States
Research Site
Burlington Vermont, 05405, United States
Research Site
Seattle Washington, 98109, United States
Research Site
Birtinya , 4575, Australia
Research Site
Kogarah , 2217, Australia
Research Site
Miranda , 2228, Australia
Research Site
North Adelaide , 5000, Australia
Research Site
Orange , 2800, Australia
Research Site
Redcliffe , 4020, Australia
Research Site
Wahroonga , 2076, Australia
Research Site
Woolloongabba , 4102, Australia
Research Site
Brasschaat , 2930, Belgium
Research Site
Gent , 9000, Belgium
Research Site
Liège , 4000, Belgium
Research Site
Wilrijk , 2610, Belgium
Research Site
Yvoir , 5530, Belgium
Research Site
Cachoeiro de Itapemirim , 29308, Brazil
Research Site
Ijuí , 98700, Brazil
Research Site
Porto Alegre , 90035, Brazil
Research Site
Porto Alegre , 90110, Brazil
Research Site
Porto Alegre , 90160, Brazil
Research Site
Recife , 50040, Brazil
Research Site
Rio de Janeiro , 22281, Brazil
Research Site
Salvador , 41253, Brazil
Research Site
Salvador , 41820, Brazil
Research Site
São José Do Rio Preto - SP , 15090, Brazil
Research Site
São Paulo , 01221, Brazil
Research Site
São Paulo , 01509, Brazil
Research Site
São Paulo , 04014, Brazil
Research Site
Tres Lagoas , 79601, Brazil
Research Site
Halifax Nova Scotia, B3H 2, Canada
Research Site
Oshawa Ontario, L1G 2, Canada
Research Site
Toronto Ontario, M5G 2, Canada
Research Site
Montreal Quebec, H3T 1, Canada
Research Site
Sherbrooke Quebec, J1H 5, Canada
Research Site
Toronto , M4N 3, Canada
Research Site
Santiago , 75007, Chile
Research Site
Santiago , 75009, Chile
Research Site
Santiago , 76505, Chile
Research Site
Temuco , 47811, Chile
Research Site
Vina del Mar , 25200, Chile
Research Site
Beijing , 10002, China
Research Site
Beijing , 10003, China
Research Site
Beijing , 10005, China
Research Site
Changchun , 13001, China
Research Site
Changsha , 41000, China
Research Site
Changsha , 41001, China
Research Site
Chengdu , 61004, China
Research Site
Chengdu , 61007, China
Research Site
Chongqing , 40003, China
Research Site
Guangzhou , 51018, China
Research Site
Hangzhou , 31000, China
Research Site
Hangzhou , 31000, China
Research Site
Harbin , 15004, China
Research Site
Jiaxing , 31400, China
Research Site
Nanchang , 33001, China
Research Site
Nanjing , 21000, China
Research Site
Nantong , 22636, China
Research Site
Ningbo , 31501, China
Research Site
Shanghai , 20003, China
Research Site
Shanghai , 20004, China
Research Site
Shenyang , 11004, China
Research Site
Shenzhen , 51803, China
Research Site
Tianjin , 30005, China
Research Site
Wuhan , 43003, China
Research Site
Wuhan , 43007, China
Research Site
Yantai , 26400, China
Research Site
Zhengzhou , 45000, China
Research Site
Horovice , 268 0, Czechia
Research Site
Hradec Kralove , 500 0, Czechia
Research Site
Pardubice , 532 0, Czechia
Research Site
Praha 10 , 10034, Czechia
Research Site
Praha 4 , 14059, Czechia
Research Site
Praha 5 , 150 0, Czechia
Research Site
Bordeaux , 33076, France
Research Site
Brest , 29609, France
Research Site
Clermont-Ferrand CEDEX 01 , 63011, France
Research Site
Montpellier , 34000, France
Research Site
Paris Cedex 05 , 75248, France
Research Site
Paris , 75014, France
Research Site
Rouen , 76031, France
Research Site
Saint Herblain Cedex , 44805, France
Research Site
Saint-Mande , 94160, France
Research Site
Strasbourg , 67000, France
Research Site
Vandoeuvre Les Nancy , 54000, France
Research Site
Villejuif Cedex , 94805, France
Research Site
Athens , 115 2, Greece
Research Site
Athens , 155 6, Greece
Research Site
Chaidari , 124 6, Greece
Research Site
Marousi , 151 2, Greece
Research Site
Patras , 26504, Greece
Research Site
Peiraias , 185 4, Greece
Research Site
Budapest , 1097, Hungary
Research Site
Budapest , 1122, Hungary
Research Site
Budapest , 1125, Hungary
Research Site
Budapest , 1145, Hungary
Research Site
Kecskemét , 6000, Hungary
Research Site
Nyiregyhaza , 4400, Hungary
Research Site
Szeged , 6725, Hungary
Research Site
Szolnok , 5000, Hungary
Research Site
Bikaner , 33400, India
Research Site
Meerut , 25000, India
Research Site
Mohali , 16005, India
Research Site
Nashik , 42200, India
Research Site
New Delhi , 11008, India
Research Site
Chiba-shi , 260-8, Japan
Research Site
Hirakata-shi , 573-1, Japan
Research Site
Hirosaki-shi , 036-8, Japan
Research Site
Kanazawa-shi , 920-8, Japan
Research Site
Kashihara-shi , 634-8, Japan
Research Site
Kawagoe-shi , 350-8, Japan
Research Site
Kita-gun , 761-0, Japan
Research Site
Kobe-shi , 650-0, Japan
Research Site
Kumamoto-shi , 860-0, Japan
Research Site
Miyazaki-shi , 889-1, Japan
Research Site
Nagano-Shi , 381-8, Japan
Research Site
Nagoya-shi , 466-8, Japan
Research Site
Nakano-Ku , 164-0, Japan
Research Site
Osaka-shi , 541-8, Japan
Research Site
Osakasayama-shi , 589-8, Japan
Research Site
Sagamihara-shi , 252-0, Japan
Research Site
Sapporo-shi , 003-0, Japan
Research Site
Tsu-shi , 514-8, Japan
Research Site
Wakayama-shi , 641-8, Japan
Research Site
Yokohama-shi , 232-0, Japan
Research Site
Bukgu , 41404, Korea, Republic of
Research Site
Busan , 602-7, Korea, Republic of
Research Site
Goyang-si , 10408, Korea, Republic of
Research Site
Seoul , 03080, Korea, Republic of
Research Site
Seoul , 05505, Korea, Republic of
Research Site
Seoul , 06591, Korea, Republic of
Research Site
Seoul , 120-7, Korea, Republic of
Research Site
Seoul , 135-7, Korea, Republic of
Research Site
Aguascalientes , 20116, Mexico
Research Site
Cancún , 77500, Mexico
Research Site
Ciudad de México , 03840, Mexico
Research Site
Culiacan , 80230, Mexico
Research Site
Culiacán , 80020, Mexico
Research Site
Guadalajara , 44260, Mexico
Research Site
Guadalajara , 44680, Mexico
Research Site
Mexico , 04700, Mexico
Research Site
Oaxaca , 68000, Mexico
Research Site
Zapopan , 45116, Mexico
Research Site
Den Haag , 2545 , Netherlands
Research Site
Hoofddorp , 2134 , Netherlands
Research Site
Konin , 62-50, Poland
Research Site
Lodz , 93-51, Poland
Research Site
Nowa Sol , 67-10, Poland
Research Site
Opole , 45-06, Poland
Research Site
Warszawa , 02-78, Poland
Research Site
Wieliszew , 05-13, Poland
Research Site
Barcelona , 08003, Spain
Research Site
Barcelona , 08035, Spain
Research Site
Barcelona , 08036, Spain
Research Site
Barcelona , ?0804, Spain
Research Site
Cordoba , 14004, Spain
Research Site
Lugo , 27003, Spain
Research Site
Madrid , 28034, Spain
Research Site
Madrid , 28040, Spain
Research Site
Madrid , 28041, Spain
Research Site
Malaga , 29010, Spain
Research Site
Sabadell , 08208, Spain
Research Site
Sevilla , 41013, Spain
Research Site
Kaohsiung , 81362, Taiwan
Research Site
Taichung , 40044, Taiwan
Research Site
Taichung , 40447, Taiwan
Research Site
Tainan , 704, Taiwan
Research Site
Tainan , 710, Taiwan
Research Site
Taipei , 10002, Taiwan
Research Site
Taipei , 11259, Taiwan
Research Site
Bristol , BS2 8, United Kingdom
Research Site
Edinburgh , EH4 2, United Kingdom
Research Site
Guildford , , United Kingdom
Research Site
Hackensack , 07601, United Kingdom
Research Site
Hampstead , NW3 2, United Kingdom
Research Site
London , SE1 9, United Kingdom
Research Site
London , SW7 3, United Kingdom
Research Site
Manchester , M20 4, United Kingdom
Research Site
Southampton , SO16 , United Kingdom
Research Site
Sutton , SM2 5, United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 3

Estimated Enrollment:

790

Study ID:

NCT05348577

Recruitment Status:

Recruiting

Sponsor:


AstraZeneca

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.